• Markets
    • icon
  • Companies
IMM · ASX

Immutep Ltd (ASX:IMM)

AU$0.34

 0.005 (1.493%)
ASX:Live
26/07/2024 04:10:15 PM
Recent Price downgrade Hammer Bullish HALO Ords HALO Momentum HALO Earnings Momentum +6
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

IMM Overview

IMM Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Weak

Earnings

Very Weak

Growth

Earnings

Weak

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Neutral

About IMM

Website

Immutep Ltd

Telephone

61.2.8315.7003

Address

Level 32, Suite 32.07 264 George Street Australia Square Sydney, New South Wales (NSW) 2000

Description

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987, and is headquartered in Sydney, Australia.

IMM Price Chart

Key Stats

Market Cap

AU$404.20M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.23 - 0.48

Trade Value (12mth)

AU$191,750.00

1 week

13.56%

1 month

-22.99%

YTD

-2%

1 year

4.03%

All time high

4.07

Key Fundamentals

EPS 3 yr Growth

33.000%

EBITDA Margin

N/A

Operating Cashflow

-$35m

Free Cash Flow Return

-30.30%

ROIC

-34.20%

Interest Coverage

-2,101.60

Quick Ratio

13.80

Other Data

Shares on Issue (Fully Dilluted)

1197m

HALO Sector

Healthcare

Next Company Report Date

28-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.14

IMM Announcements

Latest Announcements

Date Announcements

22 July 24

Successful Meeting with FDA on Phase III Design in NSCLC

×

Successful Meeting with FDA on Phase III Design in NSCLC

17 July 24

Regulatory Clearance received for Phase 1 trial of IMP761

×

Regulatory Clearance received for Phase 1 trial of IMP761

12 July 24

Webcast to discuss data presented at ESMO Plenary Session

×

Webcast to discuss data presented at ESMO Plenary Session

12 July 24

Positive results in TACTI-003 for 1L HNSCC cohort B patients

×

Positive results in TACTI-003 for 1L HNSCC cohort B patients

12 July 24

Becoming a substantial holder

×

Becoming a substantial holder

04 July 24

Change in substantial holding

×

Change in substantial holding

03 July 24

Details for Immutep Webcast & ESMO Virtual Plenary Session

×

Details for Immutep Webcast & ESMO Virtual Plenary Session

27 June 24

Positive topline results from ph2b in head & neck cancer

×

Positive topline results from ph2b in head & neck cancer

27 June 24

Webcast slides for new Efti clinical data in 1st line HNSCC

×

Webcast slides for new Efti clinical data in 1st line HNSCC

25 June 24

Immutep signs agreement for anti-LAG-3 small molecules

×

Immutep signs agreement for anti-LAG-3 small molecules

25 June 24

Application for quotation of securities - IMM

×

Application for quotation of securities - IMM

24 June 24

Immutep completes underwritten retail entitlement offer

×

Immutep completes underwritten retail entitlement offer

18 June 24

Change in substantial holding from IFL

×

Change in substantial holding from IFL

14 June 24

Change in substantial holding

×

Change in substantial holding

14 June 24

Change in substantial holding

×

Change in substantial holding

12 June 24

Application for quotation of securities - IMM

×

Application for quotation of securities - IMM

12 June 24

Cleansing Notice

×

Cleansing Notice

07 June 24

Immutep retail entitlement offer booklet

×

Immutep retail entitlement offer booklet

07 June 24

Immutep letter to ineligible shareholders

×

Immutep letter to ineligible shareholders

05 June 24

Immutep completes institutional pro-rata offer & placement

×

Immutep completes institutional pro-rata offer & placement

03 June 24

Trading Halt

×

Trading Halt

03 June 24

A$100 million fully underwritten equity raising

×

A$100 million fully underwritten equity raising

03 June 24

Immutep Capital Raising Presentation

×

Immutep Capital Raising Presentation

03 June 24

Proposed issue of securities - IMM

×

Proposed issue of securities - IMM

03 June 24

Immutep announces Ph 3 clinical trial collaboration with MSD

×

Immutep announces Ph 3 clinical trial collaboration with MSD

IMM Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.05 -0.04 -0.04 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.05 -0.04 -0.04 Lock Lock Lock
     Growth % Lock Lock Lock Lock -49.7 24.7 -17.9 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.02 -0.03 -0.03 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.03 -0.04 -0.04 Lock Lock Lock
     Growth % Lock Lock Lock Lock 6.7 -58.2 8.1 Lock Lock Lock
     Yield % Lock Lock Lock Lock -5.4 -12.3 -12.6 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.10 0.11 0.11 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.08 0.10 0.11 Lock Lock Lock
     Growth % Lock Lock Lock Lock 268.8 19.4 10.9 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 595 849 892 Lock Lock Lock
Basic m Lock Lock Lock Lock 595 849 892 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -100.0 N/A -100.0 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 21 36 43 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -2 -2 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A 8.6 -8.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A -1,111.2 N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock N/A 1,211 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -21 -36 -43 Lock Lock Lock
     Growth % Lock Lock Lock Lock -11.4 -69.3 -18.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A -21,317.2 N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 2 2 2 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -24 -38 -45 Lock Lock Lock
     Growth % Lock Lock Lock Lock -10.3 -63.2 -17.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A -22,528.4 N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -30 -32 -40 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -30 -32 -40 Lock Lock Lock
     Growth % Lock Lock Lock Lock -122.0 -7.7 -23.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A -18,906.5 N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -18 -30 -35 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 53 50 76 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -18 -30 -35 Lock Lock Lock
     Growth % Lock Lock Lock Lock -62.6 -71.3 -17.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A -177.6 N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 61 80 123 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 82 102 147 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 3 2 1 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -58 -78 -122 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 9 8 11 Lock Lock Lock
Equity $m Lock Lock Lock Lock 73 94 136 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 76 96 138 Lock Lock Lock
     Growth % Lock Lock Lock Lock 79.7 26.0 43.8 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -36.5 -31.5 -27.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -40.8 -34.2 -29.2 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -39.7 -44.7 -38.5 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -50.6 -37.6 -34.2 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -29.9 -35.2 -30.3 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -2,183.1 -392.9 -2,101.6 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 2.7 2.2 2.8 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -78.9 -83.2 -89.5 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 12.8 14.2 13.8 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 12.8 14.2 13.8 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 88.6 88.1 91.4 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -330.3 -471.3 -361.8 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock N/A 1,682.3 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock N/A -18,906.5 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock N/A -31.5 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -36.5 -31.5 -27.1 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.1 1.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -40.8 -34.2 -29.2 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -40.8 -34.2 -29.2 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock N/A 15,530.4 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock N/A 15,530.4 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 305.4 414.9 735.9 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -305.4 15,115.5 -735.9 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.14%

Value ($M)

1

Prior Change

N/A

7 Day Change

N/A

1 Month Change

-0.10%

3 Month Change

0.10%

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

IMM Shortsell

Frequently Asked Questions

The current share price of Immutep Ltd (IMM:ASX) is AU$0.34.
The 52-week high share price for Immutep Ltd (IMM:ASX) is AU$0.48.
The 52-week low share price for Immutep Ltd (IMM:ASX)? is AU$0.23.
Immutep Ltd (IMM:ASX) does not pay a dividend.
Immutep Ltd (IMM:ASX) does not pay a dividend.
Immutep Ltd (IMM:ASX) has a franking level of 0.0%.
Immutep Ltd (IMM:ASX) is classified in the Healthcare.
The current P/E ratio for Immutep Ltd (IMM:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.